Search results for "Hematologic Cancers and Related Disorders"

showing 10 items of 11 documents

Identifying Prognostic SNPs in Clinical Cohorts: Complementing Univariate Analyses by Resampling and Multivariable Modeling

2016

Clinical cohorts with time-to-event endpoints are increasingly characterized by measurements of a number of single nucleotide polymorphisms that is by a magnitude larger than the number of measurements typically considered at the gene level. At the same time, the size of clinical cohorts often is still limited, calling for novel analysis strategies for identifying potentially prognostic SNPs that can help to better characterize disease processes. We propose such a strategy, drawing on univariate testing ideas from epidemiological case-controls studies on the one hand, and multivariable regression techniques as developed for gene expression data on the other hand. In particular, we focus on …

0301 basic medicineMultivariate analysisMicroarraysTest StatisticsGene Expressionlcsh:MedicineBioinformatics01 natural sciencesHematologic Cancers and Related DisordersCohort Studies010104 statistics & probabilityMathematical and Statistical TechniquesResamplingMedicine and Health Scienceslcsh:ScienceStatistical DataUnivariate analysisMultidisciplinarySimulation and ModelingMultivariable calculusRegression analysisHematologyMyeloid LeukemiaPrognosisRegressionBioassays and Physiological AnalysisOncologyResearch DesignPhysical SciencesStatistics (Mathematics)Research ArticleAcute Myeloid LeukemiaPermutationSingle-nucleotide polymorphismComputational biologyBiologyResearch and Analysis MethodsPolymorphism Single Nucleotide03 medical and health sciencesLeukemiasGeneticsHumansStatistical Methods0101 mathematicsDiscrete Mathematicslcsh:RUnivariateCancers and NeoplasmsBiology and Life SciencesModels Theoretical030104 developmental biologyCombinatoricsCase-Control StudiesMultivariate Analysislcsh:QMathematicsPLOS ONE
researchProduct

Single-Nucleotide Polymorphism Array-Based Karyotyping of Acute Promyelocytic Leukemia

2014

Acute promyelocytic leukemia (APL) is characterized by the t(15;17)(q22;q21), but additional chromosomal abnormalities (ACA) and other rearrangements can contribute in the development of the whole leukemic phenotype. We hypothesized that some ACA not detected by conventional techniques may be informative of the onset of APL. We performed the high-resolution SNP array (SNP-A) 6.0 (Affymetrix) in 48 patients diagnosed with APL on matched diagnosis and remission sample. Forty-six abnormalities were found as an acquired event in 23 patients (48%): 22 duplications, 23 deletions and 1 Copy-Neutral Loss of Heterozygocity (CN-LOH), being a duplication of 8(q24) (23%) and a deletion of 7(q33-qter) (…

AdultMaleAcute promyelocytic leukemiamedicine.medical_specialtyAdolescentOncogene Proteins FusionMicroarrayslcsh:MedicineLoss of HeterozygosityChromosomal translocationBiologyResearch and Analysis MethodsPolymorphism Single NucleotideTranslocation GeneticHematologic Cancers and Related DisordersLoss of heterozygosityYoung AdultLeukemia Promyelocytic AcuteLeukemiasGene duplicationMedicine and Health SciencesmedicineHumanslcsh:ScienceAgedChromosome AberrationsChromosomes Human Pair 15Multidisciplinarylcsh:RBreakpointCytogeneticsBiology and Life SciencesComputational BiologyHematologyMiddle AgedPrognosismedicine.diseaseMolecular biologyLeukemiaBioassays and Physiological AnalysisKaryotypingCancer researchlcsh:QFemaleResearch ArticleChromosomes Human Pair 17SNP arrayPLoS ONE
researchProduct

Survival of Adults with Acute Lymphoblastic Leukemia in Germany and the United States

2014

BackgroundAdulthood acute lymphoblastic leukemia (ALL) is a rare disease. In contrast to childhood ALL, survival for adults with ALL is poor. Recently, new protocols, including use of pediatric protocols in young adults, have improved survival in clinical trials. Here, we examine population level survival in Germany and the United States (US) to gain insight into the extent to which changes in clinical trials have translated into better survival on the population level.MethodsData were extracted from the Surveillance, Epidemiology, and End Results database in the US and 11 cancer registries in Germany. Patients age 15-69 diagnosed with ALL were included. Period analysis was used to estimate…

AdultMalePediatricsmedicine.medical_specialtyAdolescentNon-Clinical MedicineEpidemiologyScienceLymphoblastic LeukemiaBiostatisticsHematologic Cancers and Related DisordersGermanyLeukemiasEpidemiologyHumansMedicineStatistical MethodsYoung adultSurvival analysisAgedHealth Care PolicyMultidisciplinaryRelative survivalbusiness.industryStatisticsQRCancers and NeoplasmsCancerHematologyMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaAcute Lymphoblastic Leukemiamedicine.diseaseSurvival AnalysisUnited StatesClinical trialOncologyUnited States ; age groups ; cancer treatment ; German people ; Germany ; cancer detection and diagnosis ; acute lymphoblastic leukemia ; leukemiasMedicineFemaleHealth StatisticsbusinessMathematicsResearch ArticleRare diseasePLoS ONE
researchProduct

Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells

2012

PLoS one 7(7), e40853 (2012). doi:10.1371/journal.pone.0040853

Drugs and DevicesDrug Research and DevelopmentTime Factorsmedicine.drug_classChronic Myeloid LeukemiaIntracellular Spacelcsh:MedicineApoptosisPharmacologyPiperazinesTyrosine-kinase inhibitorHematologic Cancers and Related DisordersCell Line TumorLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesLeukemiasmedicineHumansAnnexin A5Proto-Oncogene Proteins c-abllcsh:ScienceProtein Kinase InhibitorsMyeloproliferative DisordersMultidisciplinaryABLDose-Response Relationship DrugCaspase 3Chemistrylcsh:RBiological activityImatinibHematologyrespiratory tract diseasesDasatinibKineticsPyrimidinesImatinib mesylatePharmacodynamicsBenzamidesImatinib MesylateMedicineATP-Binding Cassette Transporterslcsh:QDrug Screening Assays AntitumorSignal transductionIntracellularResearch ArticleSignal Transductionmedicine.drug
researchProduct

Correction: Association of ionizing radiation dose from common medical diagnostic procedures and lymphoma risk in the Epilymph case-control study

2020

International audience; Medical diagnostic X-rays are an important source of ionizing radiation (IR) exposure in the general population; however, it is unclear if the resulting low patient doses increase lymphoma risk. We examined the association between lifetime medical diagnostic X-ray dose and lymphoma risk, taking into account potential confounding factors, including medical history. The international Epilymph study (conducted in the Czech-Republic, France, Germany, Ireland, Italy, and Spain) collected self-reported information on common diagnostic X-ray procedures from 2,362 lymphoma cases and 2,465 frequency-matched (age, sex, country) controls. Individual lifetime cumulative bone mar…

MaleLimfomesLymphoma[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/ImagingPhysiologyLogistic regressionPediatrics030218 nuclear medicine & medical imagingDiagnostic RadiologyHematologic Cancers and Related Disorders0302 clinical medicineRisk FactorsBone MarrowRadiation IonizingImmune PhysiologyOdds RatioMedicine and Health SciencesMedicineFamily historyCàncerCancerCancer risk factorseducation.field_of_studyMultidisciplinaryFactors de risc en les malaltiesRadiology and ImagingQConfoundingRHematologyMiddle AgedRadiation ExposureBone Imaging3. Good healthOncology030220 oncology & carcinogenesisMedicineFemaleLymphomasResearch ArticleAdultmedicine.medical_specialtyRisk factors in diseasesImaging TechniquesSciencePopulationImmunology[SDV.CAN]Life Sciences [q-bio]/CancerRadiation DosageResearch and Analysis Methods03 medical and health sciences[SDV.CAN] Life Sciences [q-bio]/CancerRheumatologyDiagnostic MedicineInternal medicineOsteoarthritisCancer Detection and DiagnosisHumansMedical historyeducationAgedbusiness.industryArthritisCase-control studyCorrectionCancers and NeoplasmsBiology and Life SciencesOdds ratiomedicine.diseaseLymphomaX-Ray RadiographyMedical risk factorsLogistic Models[SDV.IB.IMA] Life Sciences [q-bio]/Bioengineering/Imaging[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieCase-Control StudiesImmune System[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessPLoS ONE
researchProduct

SNPs array karyotyping reveals a novel recurrent 20p13 amplification in primary myelofibrosis.

2011

The molecular pathogenesis of primary mielofibrosis (PMF) is still largely unknown. Recently, single-nucleotide polymorphism arrays (SNP-A) allowed for genome-wide profiling of copy-number alterations and acquired uniparental disomy (aUPD) at high-resolution. In this study we analyzed 20 PMF patients using the Genome-Wide Human SNP Array 6.0 in order to identify novel recurrent genomic abnormalities. We observed a complex karyotype in all cases, detecting all the previously reported lesions (del(5q), del(20q), del(13q), +8, aUPD at 9p24 and abnormalities on chromosome 1). In addition, we identified several novel cryptic lesions. In particular, we found a recurrent alteration involving cytob…

MaleMicroarraysMIELOFIBROSISChromosomes Human Pair 20Loss of Heterozygositylcsh:MedicineLoss of heterozygosityCohort StudiesHematologic Cancers and Related DisordersGene duplicationTaq Polymeraselcsh:ScienceOligonucleotide Array Sequence AnalysisMultidisciplinaryMYELOFIBROSIS; SNPKaryotypeGenomicsHematologyUniparental disomyMedicineFemaleImmunohistochemical AnalysisSNP arrayResearch ArticleTest Evaluationmedicine.medical_specialtyDNA Copy Number VariationsImmunologySNPLocus (genetics)Single-nucleotide polymorphismReceptors Cell SurfaceBiologyPolymorphism Single NucleotideDiagnostic MedicinemedicineGeneticsHumansBiologyAgedEvolutionary BiologyMyeloproliferative DisordersPopulation Biologylcsh:RCytogeneticsGene AmplificationComputational BiologyDNAUniparental Disomymedicine.diseaseMolecular biologyMYELOFIBROSISPrimary MyelofibrosisKaryotypingGenetic PolymorphismImmunologic TechniquesClinical Immunologylcsh:QPopulation GeneticsPLoS ONE
researchProduct

Assessment of the impact of inpatient infectious events in pediatric patients with newly diagnosed acute leukemia at Dr. Robert Reid Cabral Children’…

2020

Survival rates for pediatric acute leukemia vary dramatically worldwide. Infections are a leading cause of morbidity and mortality, and the impact is amplified in low and middle-income countries. Defining the epidemiology of infection in a specific health care setting is paramount to developing effective interventions. This study aimed to define the epidemiology of and outcomes from infection in children with acute leukemia treated in a large public pediatric hospital in the Dominican Republic. A retrospective cohort was assembled of children newly diagnosed with acute leukemia between July 1, 2015 to June 30, 2017 at Hospital Infantil Dr. Robert Reid Cabral in Santo Domingo. Patients were …

MalePediatricsPulmonologyEpidemiologyNosocomial InfectionsPhysiologyPediatricsHematologic Cancers and Related Disorders0302 clinical medicineMedical ConditionsEpidemiologyMedicine and Health SciencesInfection controlAntimicrobial stewardshipMedicineChildAcute leukemiaMultidisciplinaryLeukemiaMedical recordCancer Risk FactorsQRHematologyMyeloid LeukemiaHospitals PediatricPrognosisHospitalsBody FluidsLeukemia Myeloid AcuteInfectious DiseasesBloodOncology030220 oncology & carcinogenesisChild PreschoolCohortMedicineFemaleAnatomyPediatric InfectionsResearch ArticleAcute Myeloid Leukemiamedicine.medical_specialtyAdolescentScienceInfections03 medical and health sciencesRespiratory DisordersDiagnostic MedicineCancer Detection and DiagnosisHumansRetrospective StudiesInpatientsbusiness.industryDominican RepublicCancers and NeoplasmsBiology and Life SciencesInfantRetrospective cohort studymedicine.diseaseBacteremiaMedical Risk FactorsRespiratory Infectionsbusiness030215 immunologyPLoS ONE
researchProduct

Adherence to immunomodulatory drugs in patients with multiple myeloma

2018

Background Immunomodulatory drugs (thalidomide, lenalidomide and pomalidomide; IMID) are widely used in the treatment of multiple myeloma patients. To date, few data are available on IMID adherence in multiple myeloma patients. The aim of our study was to evaluate IMID adherence and to compare two indirect methods to measure IMID adherence in multiple myeloma patients: a specific questionnaire and the medication possession ratio (MPR). Another aim was to explore this specific questionnaire for the assessment of IMID adherence in multiple myeloma patients. Methods All consecutive multiple myeloma patients, with at least two consecutive dispensations of thalidomide, lenalidomide or pomalidomi…

MaleQuestionnairesCancer Treatment030204 cardiovascular system & hematologyPharmacistsPlasma Cell DisordersHematologic Cancers and Related DisordersMathematical and Statistical Techniques0302 clinical medicineSurveys and QuestionnairesMedicine and Health SciencesMedical PersonnelProspective StudiesProspective cohort studyMultiple myelomaMultidisciplinaryQStatisticsRHematologyMyelomasProfessionsOncologyResearch Design030220 oncology & carcinogenesisPhysical SciencesMedicineRegression AnalysisFemaleMultiple MyelomaResearch Articlemedicine.drugmedicine.medical_specialtyDrug AdherenceClinical Research DesignScienceLinear Regression AnalysisResearch and Analysis MethodsMedication Adherence03 medical and health sciencesCronbach's alphaInternal medicinemedicineHumansImmunologic FactorsIn patientMyelomas and Lymphoproliferative DiseasesStatistical MethodsAdverse effectAgedLenalidomidePharmacologySurvey Researchbusiness.industryCancers and NeoplasmsPomalidomidemedicine.diseaseThalidomidePeople and PlacesPopulation GroupingsAdverse EventsbusinessMathematicsPLOS ONE
researchProduct

Carboxyamidotriazole-Orotate Inhibits the Growth of Imatinib-Resistant Chronic Myeloid Leukaemia Cells and Modulates Exosomes-Stimulated Angiogenesis

2012

The Bcr/Abl kinase has been targeted for the treatment of chronic myelogenous leukaemia (CML) by imatinib mesylate. While imatinib has been extremely effective for chronic phase CML, blast crisis CML are often resistant. New therapeutic options are therefore needed for this fatal disease. Although more common in solid tumors, increased microvessel density was also reported in chronic myelogenous leukaemia and was associated with a significant increase of angiogenic factors, suggesting that vascularity in hematologic malignancies is a controlled process and may play a role in the leukaemogenic process thus representing an alternative therapeutic target. Carboxyamidotriazole-orotate (CTO) is …

MaleResearch ValidityPhysiologyAngiogenesisTumor PhysiologyFusion Proteins bcr-ablCancer Treatmentlcsh:MedicinePharmacologyExosomesCardiovascular PhysiologyBiochemistryPiperazinesHematologic Cancers and Related DisordersMicechemistry.chemical_compoundCell Movementhemic and lymphatic diseasesMolecular Cell BiologyBasic Cancer ResearchMedicine and Health SciencesPhosphorylationPost-Translational ModificationExtracellular Signal-Regulated MAP Kinaseslcsh:ScienceChronic Myelogenous LeukemiaMultidisciplinaryABLNeovascularization PathologicGene Expression Regulation LeukemicChemistryHematologyResearch AssessmentOncologyBenzamidesImatinib MesylateMedicineOncology AgentsAntiangiogenesis Therapymedicine.drugResearch ArticleChronic Myeloid LeukemiaAntineoplastic AgentsResearch and Analysis MethodsCell GrowthCell Line TumorLeukemia Myelogenous Chronic BCR-ABL PositiveLeukemiasCell AdhesionHuman Umbilical Vein Endothelial CellsmedicineAnimalsHumansRNA MessengerPhosphotyrosineBiologyCell ProliferationOrotic AcidTumor microenvironmentCarboxyamidotriazoleInterleukin-8lcsh:RBiology and Life SciencesProteinsCancers and NeoplasmsImatinibTriazolesmedicine.diseaseXenograft Model Antitumor AssaysRetractionExosomePyrimidinesImatinib mesylateDrug Resistance NeoplasmCarboxyamidotriazole Orotatelcsh:QAngiogenesisCell Adhesion MoleculesProto-Oncogene Proteins c-aktDevelopmental BiologyChronic myelogenous leukemiaPLoS ONE
researchProduct

Bleomycin Exerts Ambivalent Antitumor Immune Effect by Triggering Both Immunogenic Cell Death and Proliferation of Regulatory T Cells

2013

International audience; Bleomycin (BLM) is an anticancer drug currently used for the treatment of testis cancer and Hodgkin lymphoma. This drug triggers cancer cell death via its capacity to generate radical oxygen species (ROS). However, the putative contribution of anticancer immune responses to the efficacy of BLM has not been evaluated. We make here the observation that BLM induces immunogenic cell death. In particular, BLM is able to induce ROS-mediated reticulum stress and autophagy, which result in the surface exposure of chaperones, including calreticulin and ERp57, and liberation of HMBG1 and ATP. BLM induces anti-tumor immunity which relies on calreticulin, CD8(+) T cells and inte…

MouseCancer TreatmentCD8-Positive T-LymphocytesT-Lymphocytes RegulatoryHematologic Cancers and Related DisordersMice0302 clinical medicineTransforming Growth Factor beta[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyCytotoxic T cellImmune Response0303 health sciencesMultidisciplinaryCell DeathbiologyQRFOXP3Animal ModelsHematology3. Good healthCell biologyOncology030220 oncology & carcinogenesisMedicine[SDV.IMM]Life Sciences [q-bio]/ImmunologyImmunogenic cell deathFemaleLymphomasOncology AgentsResearch ArticleTumor Immunologycongenital hereditary and neonatal diseases and abnormalitiesProgrammed cell death[SDV.IMM] Life Sciences [q-bio]/ImmunologyScienceImmunologyAntineoplastic Agentschemical and pharmacologic phenomenaBleomycin03 medical and health sciencesModel OrganismsImmune systemCell Line TumorAnimalsHumansBiologyCell Proliferation030304 developmental biologyHodgkin Lymphomaurogenital systemCell growthImmunitynutritional and metabolic diseasesImmunologic SubspecialtiesChemotherapy and Drug TreatmentImmunity InnateCancer cellbiology.proteinClinical ImmunologyCalreticulinPLoS ONE
researchProduct